Key takeaways
Levemir (insulin detemir) and Tresiba (insulin degludec) are both long-acting insulins used to control high blood sugar levels in people with type 1 and type 2 diabetes. Levemir can be injected once or twice daily, while Tresiba is typically injected once daily and can be taken at any time of the day. Tresiba lasts longer than Levemir, with its pens being good for up to 56 days at room temperature once opened, compared to Levemir's 42 days. Levemir is available in both vials and pens, whereas Tresiba is only available in pens. Levemir has a lower risk of weight gain compared to some other insulins, but Tresiba uses one of the smallest needles possible, making injections potentially less painful. Both medications can cause low blood sugar and should not be mixed with other insulins. Tresiba is only available as a brand name, which can make it expensive. Levemir Flexpens has been discontinued as of April 2024, and vials will be discontinued by December 2024.
